Diabetic wounds are notoriously difficult to heal due to a combination of impaired angiogenesis, persistent inflammation, and frequent microbial infection. Conventional treatments often fail to address these multifactorial challenges simultaneously, resulting in prolonged healing times and high recurrence rates. To tackle this complex pathology, we developed a smart hydrogel system capable of sequential, stimulus-responsive drug release specifically tailored to the stages of wound healing.
The hydrogel is based on gelatin modified with 3-carboxy-phenylboronic acid (3-carboxy-BA), which enables dual responsiveness to pH and reactive oxygen species (ROS)—both elevated in inflamed diabetic wounds. This functionalization allows the hydrogel to remain intact under normal conditions but rapidly degrade when exposed to the acidic and oxidative environment characteristic of chronic inflammation. The degradation triggers the release of two therapeutic agents in a precisely timed sequence: first, vancomycin-conjugated silver nanoclusters (VAN-AgNCs) for immediate antibacterial action, followed by nimesulide-loaded pH-sensitive micelles to suppress inflammatory responses.
The VAN-AgNCs component acts through multiple mechanisms: membrane disruption, intracellular ROS generation, and DNA damage, effectively targeting both Gram-positive and Gram-negative bacteria commonly found in diabetic ulcers. Upon initial release, these nanoclusters significantly reduce bacterial load at the wound site. As the wound progresses into the proliferative phase, the local pH drops further, triggering the disassembly of the micellar structure and sustained release of nimesulide—a nonsteroidal anti-inflammatory drug (NSAID) known for its ability to inhibit COX-2 and reduce pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.UHRF1 Antibody Epigenetic Reader Domain
This sequential delivery strategy mimics the natural progression of wound healing—first controlling infection, then resolving inflammation. In vitro studies confirmed that the hydrogel exhibited strong antimicrobial activity against S. aureus and P. aeruginosa, with over 90% bacterial reduction observed within 12 hours. Additionally, the hydrogel demonstrated excellent biocompatibility, with minimal hemolysis and no significant cytotoxicity toward fibroblasts and endothelial cells. Importantly, the hydrogel enhanced cell migration and proliferation even under inflammatory stress induced by LPS, suggesting a supportive role in tissue regeneration.
In vivo evaluation using a streptozotocin-induced diabetic rat model revealed remarkable improvements in wound healing. Animals treated with the hydrogel showed accelerated wound closure, reaching over 80% re-epithelialization by day 7 and nearly complete healing by day 14. Histological analysis demonstrated increased collagen deposition, reduced inflammatory infiltrate, and robust neovascularization compared to control groups. Immunohistochemistry confirmed a significant downregulation of TNF-α and IL-6, along with upregulated expression of VEGF and CD31, indicating enhanced angiogenesis.
Moreover, the hydrogel displayed excellent physical properties: it was injectable, self-healing, and capable of conforming to irregular wound shapes.PRMT6 Antibody Technical Information Rheological testing confirmed high elasticity and rapid recovery after deformation, essential for maintaining structural integrity during wound movement.PMID:34223713 The hydrogel also exhibited strong hemostatic capability, reducing bleeding time in liver injury models and promoting red blood cell adhesion via gelatin’s inherent RGD motifs.
These results highlight the potential of this inflammation-responsive hydrogel as a next-generation wound dressing for chronically infected diabetic wounds. Its ability to deliver therapeutics in a spatiotemporally controlled manner—responding dynamically to the wound microenvironment—represents a paradigm shift from passive dressings to intelligent, adaptive therapies. By addressing infection early and modulating inflammation later, this system not only accelerates healing but also reduces the risk of complications, offering a promising solution for one of the most challenging problems in modern medicine.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com